If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Cyramza ® (ramucirumab) injection
10 mg/mL solutionThis information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Ramucirumab: Approval for Treatment of NSCLC
In the US, ramucirumab, in combination with erlotinib, is indicated for the first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.
On May 29, 2020, the FDA approved ramucirumab, in combination with erlotinib, for the first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.1
Enclosed Prescribing Information
CYRAMZA® (ramucirumab) injection, for intravenous use, Lilly
1. Cyramza [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.
Glossary
EGFR = epidermal growth factor receptor
FDA = Food and Drug Administration
NSCLC = non-small cell lung cancer
Date of Last Review: May 29, 2020
Contact Lilly
Call Us
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon - Fri, 8am - 7pm ET
